Compound tracker

methylone.

A source-backed research page for trial rows and update notes connected to this compound or investigational product. The page is generated from the Notion tracker and should be read as a living research map, not a medical conclusion.

0 trial rows 1 update rows Latest checked: May 17, 2026 All trials

Claim boundary

Trial registration, company topline, CNPV/rolling-review status, recruitment status, public-dashboard data, or review literature do not equal approval, label, reimbursement, access, safety, or efficacy. Related update rows are shown only when they include visible Last checked text and an explicit Claim boundary.

Backlinks

This page links out to registry/source records, the global trial tracker, the updates feed, and matching wiki dossiers when available.

Trial rows

—

Phases tracked

—

Statuses seen

Trial rows

No Notion trial rows are currently linked to this compound.

Related updates

May 17, 2026 Last checked 2026-05-17 07:00 UTC Regulation FDA

FDA CNPV psychedelic indications — psilocybin/MDD company still unnamed

Claim boundary.regulatory-process/indication list only; not approval, not safety/effectiveness finding, not label/access/reimbursement, and not primary confirmation of the psilocybin/MDD sponsor.

Last checked: 2026-05-17 07:00 UTC. FDA EO/CNPV page still names voucher indications — psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for PTSD — but does not name the psilocybin/MDD company. Claim boundary: regulatory-process/indication list only; not approval, not safety/effectiveness finding, not label/access/reimbursement, and not primary confirmation of the psilocybin/MDD sponsor.

Source/tracker note

FDA page excerpt in direct scrape: national priority vouchers to companies studying psilocybin for TRD, psilocybin for MDD, methylone for PTSD; no company named for psilocybin/MDD in checked text.

Conditions touched

No condition metadata loaded.